FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Figg

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Michael S Gordon; Bryan R Leigh; Lili Liu; David Mendelson; Ramesh K Ramanathan; Lee S Rosen; Shawn Spencer; Charles P Theuer; Bonne J Adams; Stephen P Anthony; William D Figg; Stanton L Gerson; Jonathan Goldman; Yan Xu; Glen J Weiss
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
Cody J Peer; Mahadev Rao; David S Schrump; Shandiz Shahbazi; Shawn D Spencer; Patricia S Steeg; William D Figg
A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.
Brad Moriyama; Scott R Penzak; ALAN WAYNE; Robert L Danner; William D Figg; Stacey A Henning; Paul F Jarosinski; THOMAS WALSH
Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Figg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Michael S Gordon; Bryan R Leigh; Lili Liu; David Mendelson; Ramesh K Ramanathan; Lee S Rosen; Shawn Spencer; Charles P Theuer; Bonne J Adams; Stephen P Anthony; William D Figg; Stanton L Gerson; Jonathan Goldman; Yan Xu; Glen J Weiss
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
Investigational new drugs 2013;31(3):714-23.
2013: Cody J Peer; Mahadev Rao; David S Schrump; Shandiz Shahbazi; Shawn D Spencer; Patricia S Steeg; William D Figg
A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013;927():142-6.
2013: Brad Moriyama; Scott R Penzak; ALAN WAYNE; Robert L Danner; William D Figg; Stacey A Henning; Paul F Jarosinski; THOMAS WALSH
Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
Pharmacotherapy 2013;33(3):e19-22.
2013: Connor Hall; Douglas K Price; Sarah M Troutman; William D Figg; Min H Kang
Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.
Clinical genitourinary cancer 2013;11(1):10-9.
2013: Marian L Neuhouser; Howard L Parnes; Elizabeth A Platz; William D Figg; Phyllis J Goodman; Ashraful Hoque; Ann W Hsing; Alan Kristal; M Scott Lucia; Catherine M Tangen; Yuzhen Tao; Ian M Thompson; Cathee Till; Michael Pollak
Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.
Cancer prevention research (Philadelphia, Pa.) 2013;6(2):91-9.
2013: Linda M Johnson; Douglas K Price; William D Figg
Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment.
Cancer biology & therapy 2013;14(2):90-1.
2013: Austin Duffy; William D Figg; Suzanne Fioravanti; Jaba Gamrekelashvili; Lydia Haile; Tamar Kapanadze; Chi Ma; Fei Zhao; Kathryn Compton; Tim F Greten
Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies.
Cancer immunology, immunotherapy : CII 2013;62(2):299-307.
2013: Thomas A Waldmann; TatYana A Worthy; Michael N Petrus; Mark Raffeld; Shawn D Spencer; Donn M Stewart; Paul S Albert; B Bryant; Kevin C Conlon; Stephen Creekmore; Jean R Decker; William D Figg; Thomas A Fleisher; Carolyn K Goldman; John Janik; John C Morris
Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia.
Blood 2013;121(3):476-84.
2013: Rui Gao; Douglas K Price; Kelie M Reece; Eddie Reed; Tristan Sissung; Shawn D Spencer; David J Venzon; Samuel H Fu; William D Figg
Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?
BMJ open 2013;3(1):.
2013: Joshua P Lewis; Braxton D Mitchell; Jeffrey R O'Connell; Michael A Pacanowski; Cody J Peer; Kathleen Ryan; Kevin P Bliden; Sumbul Chai; William D Figg; Quince Gibson; Paul A Gurbel; Richard B Horenstein; Shawn D Spencer; Keith Tanner; Udaya S Tantry; Alan R Shuldiner
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
Pharmacogenetics and genomics 2013;23(1):1-8.
2012: Elias Pratt; Tristan Sissung; William D Figg
Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer.
Cancer biology & therapy 2012;13(14):1374-5.
2012: William D Figg
How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancer.
Cancer biology & therapy 2012;13(12):1141-2.
2012: Alan R Kristal; Scott M Lippman; Marian L Neuhouser; Sherfaraz K Patel; Elizabeth A Platz; Juergen K Reichardt; Frank Z Stanczyk; Catherine M Tangen; Ian M Thompson; Cathee Till; Adrie Van Bokhoven; Lisa W Chu; William D Figg; Phyllis J Goodman; Ashraful Hoque; Ann W Hsing
Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012;21(10):1823-32.
2012: Cindy H Chau; William D Figg
Aflibercept in pediatric solid tumors: moving beyond the trap.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(18):4868-71.
2012: Lee S Rosen; Ben K Seon; Shawn Spencer; Charles P Theuer; Michael K Wong; Bonne J Adams; Delia Alvarez; William D Figg; Jonathan Goldman; Herbert I Hurwitz; Bryan R Leigh; David S Mendelson; Michael S Gordon
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(17):4820-9.
2012: Shawn Spencer; Bernard L Marini; William D Figg
Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.
Anticancer research 2012;32(7):2391-8.
2012: Duoli Guo; Sean O'Connell; Steven Pisle; S Esmail Tabibi; James P Cain; William D Figg; Erin R Gardner; Samuel H Yalkowsky
Preformulation study of NSC-726796.
AAPS PharmSciTech 2012;13(2):661-73.
2012: Cody J Peer; Emily D Richardson; Tristan Sissung; Sarah M Troutman; David Venzon; BRIGITTE WIDEMANN; Sukyung Woo; Robert Yarchoan; William Dahut; Bevin C English; Joel Federspiel; Erin R Gardner; Giuseppe Giaccone; Lokesh Jain; Aerang Kim; C Tyler Kirkland; Elise Kohn; Shivaani Kummar; William D Figg
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(7):2099-107.
2012: Xiaohong Chen; Cody J Peer; Shawn D Spencer; Tian Tian; Raul Alfaro; William D Figg
Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.
Journal of pharmaceutical and biomedical analysis 2012;62():140-8.
2012: Tessa J Campbell; Donald J Tindall; William D Figg
Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer.
Cancer biology & therapy 2012;13(5):237-8.
2012: Emily D Richardson; Douglas K Price; William D Figg
Significant addition to treatment options for bone metastasis in prostate cancer.
Cancer biology & therapy 2012;13(2):69-70.
2012: Xuan Huang; Cindy H Chau; William D Figg
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.
Journal of hematology & oncology 2012;5():35.
2012: Sarah M Troutman; David J Venzon; Bamidele A Adesunloye; Cheryl D Cropp; Xuan Huang; Fatima H Karzai; Douglas K Price; Tristan M Sissung; Shawn D Spencer; William D Figg
Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.
The oncologist 2012;17(3):312-20.
2012: Tristan M Sissung; Hyeyoung Sung; Sarah M Troutman; Susan E Bates; Tessa J Campbell; Heather M Pressler; William D Figg
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Discovery medicine 2012;13(68):19-34.
2011: Gerald E Marti; Seth M Steinberg; Maryalice Stetler-Stevenson; Tanyifor Tohnya; Therese White; Kieron Dunleavy; William D Figg; Nicole Drbohlav Grant; Elaine S Jaffe; John E Janik; Wyndham H Wilson
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
Leukemia & lymphoma 2011;52(12):2284-92.
2011: Arun Rajan; Michael Shnaidman; Jane B Trepel; Wadih M Zein; Sylvia V Alarcon; Nicoletta Brega; Sonja Crandon; William D Figg; Martin Gutierrez; Brett E Houk; Lokesh Jain; Ronan J Kelly; Yeong Sang Kim; Shivaani Kummar; Baskar Mannargudi; Giuseppe Giaccone
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6831-9.
2011: Tristan Sissung; H Pressler; D K Price; William D Figg
SLCO transport genes in prostate cancer--letter.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011;20(10):2325; author reply 2326-7.
2011: Song Yao; Christine B Ambrosone; William D Figg; Phyllis J Goodman; Ann W Hsing; Alan R Kristal; Scott M Lippman; Marian L Neuhouser; Howard L Parnes; Elizabeth A Platz; Douglas K Price; Juergen K V Reichardt; Regina M Santella; Frank Z Stanczyk; Li Tang; Catherine M Tangen; Ian M Thompson; Cathee Till; Ashraful Hoque
Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.
Cancer causes & control : CCC 2011;22(8):1121-31.
2011: Lokesh Jain; Elise C Kohn; Shivaani Kummar; Diane R Mould; Jürgen Venitz; Sukyung Woo; Robert Yarchoan; William L Dahut; Erin R Gardner; Giuseppe Giaccone; William D Figg
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
British journal of clinical pharmacology 2011;72(2):294-305.
2011: Richard L Piekarz; Robin Frye; H Miles Prince; Mark H Kirschbaum; Jasmine Zain; Steven Allen; Elaine S Jaffe; Alexander Ling; Maria Turner; Cody J Peer; William D Figg; Seth M Steinberg; Sonali Smith; David Joske; Ian Lewis; Laura Hutchins; Michael Craig; Antonio Tito Fojo; John J Wright; Susan E Bates
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Blood 2011;117(22):5827-34.
2011: Beata Holkova; Loveleen Kang; Sarah Kolla; Cody Peer; E Brent Perkins; Viswanathan Ramakrishnan; John D Roberts; G David Roodman; Ellen Shrader; Robert K Stuart; Daniel M Sullivan; Neha Talreja; Mary Beth Tombes; Martha D Wellons; John Wright; Domenico Coppola; Jana Lynn Dawson; Austin Doyle; William D Figg; Kevin T Hogan; Steven Grant
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(10):3388-97.
2011: Thomas A Waldmann; Enrico Lugli; Mario Roederer; Liyanage P Perera; Jeremy V Smedley; Rhonda P Macallister; Carolyn K Goldman; B Bryant; Jean M Decker; Thomas A Fleisher; H Clifford Lane; Michael C Sneller; Roger J Kurlander; David E Kleiner; John M Pletcher; William D Figg; Jason L Yovandich; Stephen P Creekmore
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
Blood 2011;117(18):4787-95.
2011: Rui Gao; Kelie Reece; Tristan Sissung; Eddie Reed; Douglas K Price; William D Figg
The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.
Mutation research 2011;708(1-2):21-7.
2011: Cody J Peer; Tristan Sissung; William D Figg
CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents.
Cancer biology & therapy 2011;11(6):549-51.
2011: Wilfred D Stein; James L Gulley; Jeff Schlom; Ravi A Madan; William Dahut; William D Figg; Yang-Min Ning; Phil M Arlen; Doug Price; Susan E Bates; Tito Fojo
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):907-17.
2011: Tristan Sissung; Erin R Gardner; Richard L Piekarz; Reuben Howden; Xiaohong Chen; Sukyung Woo; Ryan Franke; James A Clark; Laura Miller-DeGraff; Seth M Steinberg; David Venzon; David J Liewehr; Steven R Kleeberger; Susan E Bates; Douglas K Price; Douglas R Rosing; Christopher Cabell; Alex Sparreboom; William D Figg
Impact of ABCB1 allelic variants on QTc interval prolongation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):937-46.
2011: Tristan Sissung; Romano Danesi; C Tyler Kirkland; Caitlin E Baum; Sandra B Ockers; Erica V Stein; David Venzon; Douglas K Price; William D Figg
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
The Journal of clinical endocrinology and metabolism 2011;96(2):E368-72.
2011: Ronan J Kelly; Deborah Draper; Clara C Chen; Robert W Robey; William D Figg; Richard L Piekarz; Xiaohong Chen; Erin R Gardner; FRANK BALIS; Aradhana Venkatesan; Seth M Steinberg; Tito Fojo; Susan E Bates
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(3):569-80.
2011: Heather Pressler; Tristan Sissung; David Venzon; Douglas K Price; William D Figg
Expression of OATP family members in hormone-related cancers: potential markers of progression.
PloS one 2011;6(5):e20372.
2011: Ryszard M Pluta; Edward H Oldfield; Kamran D Bakhtian; Ali Reza Fathi; René K Smith; Hetty L DeVroom; Masoud Nahavandi; Sukyung Woo; William D Figg; Russell R Lonser
Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers.
PloS one 2011;6(1):e14504.
2010: William D Figg; William D Figg
Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
Cancer biology & therapy 2010;10(12):1233-4.
2010: Nima Sharifi; Jun Qi; Susan Bane; Shubhada Sharma; Rui Li; Robert Robey; William D Figg; William L Farrar; David G I Kingston
Survivin is not induced by novel taxanes.
Molecular pharmaceutics 2010;7(6):2216-23.
2010: Phyllis J Goodman; Catherine M Tangen; Alan R Kristal; Ian M Thompson; M Scott Lucia; Elizabeth A Platz; William D Figg; Ashraful Hoque; Ann W Hsing; Marian L Neuhouser; Howard L Parnes; Juergen K V Reichardt; Regina M Santella; Cathee Till; Scott M Lippman
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.
Cancer prevention research (Philadelphia, Pa.) 2010;3(12):1523-33.
2010: Sarah M Troutman; Douglas K Price; William D Figg
Prostate cancer genomic signature offers prognostic value.
Cancer biology & therapy 2010;10(11):1079-80.
2010: Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Caitlin E Baum; Sandy B Ockers; Bevin C English; Lori M Minasian; Howard L Parnes; Ann W Hsing; Juergen K V Reichardt; Ashraful Hoque; Catherine M Tangen; Alan R Kristal; Ian M Thompson; William D Figg
Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.
The Journal of urology 2010;184(6):2297-302.
2010: Andrew N Freedman; Leah B Sansbury; William D Figg; Arnold L Potosky; Sheila Weiss Smith; Muin J Khoury; Stefanie A Nelson; Richard M Weinshilboum; Mark J Ratain; Howard L McLeod; Robert S Epstein; Geoffrey S Ginsburg; Richard L Schilsky; Geoffrey Liu; David A Flockhart; Cornelia M Ulrich; Robert L Davis; Lawrence J Lesko; Issam Zineh; Gurvaneet Randhawa; Christine B Ambrosone; Mary V Relling; Nat Rothman; Heng Xie; Margaret R Spitz; Rachel Ballard-Barbash; James H Doroshow; Lori M Minasian
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
Journal of the National Cancer Institute 2010;102(22):1698-705.
2010: Lokesh Jain; Erin R Gardner; Jürgen Venitz; Giuseppe Giaccone; Brett E Houk; William D Figg
Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(30):3187-92.
2010: Nicola F Smith; Sridhar Mani; Erin G Schuetz; Kazuto Yasuda; Tristan M Sissung; Susan E Bates; William D Figg; Alex Sparreboom
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
The Annals of pharmacotherapy 2010;44(11):1709-17.
2010: William D Figg; Erika K Smith; Douglas K Price; Bevin C English; Paul W Thurman; Seth M Steinberg; Ezekiel Emanuel
Disclosing a diagnosis of cancer: where and how does it occur?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(22):3630-5.
2010: Cliona Grant; Fahd Rahman; Richard Piekarz; Cody Peer; Robin Frye; Robert W Robey; Erin R Gardner; William D Figg; Susan E Bates
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Expert review of anticancer therapy 2010;10(7):997-1008.
2010: Kristina M Cook; William D Figg
Angiogenesis inhibitors: current strategies and future prospects.
CA: a cancer journal for clinicians 2010;60(4):222-43.
2010: Haihao Sun; Stephen Pisle; Erin R Gardner; William D Figg
Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.
Cancer biology & therapy 2010;10(1):38-43.
2010: Rui Gao; Douglas K Price; William L Dahut; Eddie Reed; William D Figg
Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.
Cancer biology & therapy 2010;10(1):13-8.
2010: Heather M Pressler; William D Figg
Androgen synthesis and steroid transporters in prostate cancer: rethinking the transition to CRPC.
Cancer biology & therapy 2010;9(12):1043-5.
2010: C Tyler Kirkland; Douglas K Price; William D Figg
Genetic variant associated with aggressive not indolent prostate cancer.
Cancer biology & therapy 2010;9(12):957-8.
2010: William D Figg; James L Gulley; Howard L Parnes; Douglas K Price; Seth M Steinberg; Sukyung Woo; John J Wright; Wenhui Zhu; A Seun Ajiboye; Philip M Arlen; Xiaohong Chen; William L Dahut
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
The Journal of urology 2010;183(6):2219-26.
2010: John F Deeken; T Cormier; D K Price; T M Sissung; S M Steinberg; K Tran; D J Liewehr; W L Dahut; X Miao; William D Figg
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
The pharmacogenomics journal 2010;10(3):191-9.
2010: Alan R Kristal; Douglas K Price; Cathee Till; Jeannette M Schenk; Marian L Neuhouser; Sandy Ockers; Daniel W Lin; Ian M Thompson; William D Figg
Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
The Prostate 2010;70(6):584-90.
2010: Yang-Min Ning; James L Gulley; Philip M Arlen; Sukyung Woo; Seth M Steinberg; John J Wright; Howard L Parnes; Jane Trepel; Min-Jung Lee; Yeong Sang Kim; Haihao Sun; Ravi A Madan; Lea Latham; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(12):2070-6.
2010: Kelie M Reece; William D Figg
A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targeting.
Cancer biology & therapy 2010;9(8):583-4.
2010: Seun Ajiboye; Tristan Sissung; Nima Sharifi; William D Figg
More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.
BJU international 2010;105(7):913-6.
2010: Caitlin E Baum; Douglas K Price; William D Figg
Sarcosine as a potential prostate cancer biomarker and therapeutic target.
Cancer biology & therapy 2010;9(5):341-2.
2010: Caitlin E Baum; Sandra B Ockers; Bevin C English; Douglas K Price; Oliver Sartor; William D Figg
Androgen receptor sequence and variations in several common prostate cancer cell lines.
Cancer biology & therapy 2010;9(5):383-8.
2010: Wenhui Zhu; David S Zhu; Ravi A Madan; James L Gulley; William D Figg; William L Dahut
Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.
American journal of therapeutics 2010;17(2):176-81.
2010: Paul G Kluetz; William D Figg; William L Dahut
Angiogenesis inhibitors in the treatment of prostate cancer.
Expert opinion on pharmacotherapy 2010;11(2):233-47.
2010: Haveesh Sharma; Tristan Sissung; Heather Pressler; William D Figg
Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.
Cancer biology & therapy 2010;9(3):163-5.
2010: Tristan Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Pharmacogenetics of membrane transporters: an update on current approaches.
Molecular biotechnology 2010;44(2):152-67.
2010: Bevin C English; Caitlin E Baum; David E Adelberg; Tristan Sissung; Paul G Kluetz; William L Dahut; Douglas K Price; William D Figg
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.
Therapeutics and clinical risk management 2010;6():579-83.
2010: Ilaria Pastina; Elisa Giovannetti; Aldo Chioni; Tristan M Sissung; Francesco Crea; Cinzia Orlandini; Douglas K Price; C Cianci; William D Figg; Sergio Ricci; Romano Danesi
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
BMC cancer 2010;10():511.
2010: Lokesh Jain; Tristan Sissung; Romano Danesi; Elise C Kohn; William L Dahut; Shivaani Kummar; David Venzon; David J Liewehr; Bevin C English; Caitlin E Baum; Robert Yarchoan; Giuseppe Giaccone; Jürgen Venitz; Douglas K Price; William D Figg
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Journal of experimental & clinical cancer research : CR 2010;29():95.
2010: Lokesh Jain; Erin R Gardner; William D Figg; Milica S Chernick; Heidi H Kong
Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
Pharmacotherapy 2010;30(1):52-6.
2010: Tristan Sissung; Bevin C English; David Venzon; William D Figg; John F Deeken
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.
Pharmacogenomics 2010;11(1):89-103.
2010: Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; Xiaohong Chen; William D Figg; Maria Zajac-Kaye; Min Chen; Seth M Steinberg; Christine A Muir; Mary Ann Yancey; Yvonne R Horneffer; Lamin Juwara; Giovanni Melillo; S Percy Ivy; Maria Merino; Len Neckers; Patricia S Steeg; BA Conley; Giuseppe Giaccone; James Doroshow; Anthony J Murgo
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
European journal of cancer (Oxford, England : 1990) 2010;46(2):340-7.
2010: Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; William D Figg; Giovanni Melillo; Janet Dancey; Edward A Sausville; BA Conley; Anthony J Murgo; James Doroshow
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Cancer chemotherapy and pharmacology 2010;65(2):383-9.
2010: Susan E Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko; Robin Frye; Robert W Robey; Maria Turner; Erin R Gardner; William D Figg; Seth M Steinberg; Alex Ling; Tito Fojo; Kin Wah To; Richard L Piekarz
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
British journal of haematology 2010;148(2):256-67.
2009: Cindy H Chau; William D Figg
New tricks from an old drug: a role for quinacrine in anti-cancer therapy?
Cell cycle (Georgetown, Tex.) 2009;8(24):4024-5.
2009: Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.
Anti-cancer agents in medicinal chemistry 2009;9(10):1058-69.
2009: Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5410-7.
2009: Elizabeth A Platz; Cathee Till; Phyllis J Goodman; Howard L Parnes; William D Figg; Demetrius Albanes; Marian L Neuhouser; Eric A Klein; Ian M Thompson; Alan R Kristal
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(11):2807-13.
2009: Johann G Jonsson; Tristan M Sissung; William D Figg
A genomic strategy for predicting androgen receptor activity in prostate tumors.
Cancer biology & therapy 2009;8(21):2002-3.
2009: Nilofer S Azad; Alyssa Perroy; Erin Gardner; Chiyo K Imamura; Cynthia Graves; Gisele Sarosy; Lori M Minasian; Herb Kotz; Miranda Raggio; William D Figg; Elise C Kohn
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Cancer biology & therapy 2009;8(19):1800-5.
2009: Erica V Stein; Douglas K Price; William D Figg
shRNA technology: investigating Ras-dependent cancer.
Cancer biology & therapy 2009;8(19):1798-9.
2009: Kristina M Cook; Stephen T Hilton; Jasmin Mecinovic; William B Motherwell; William D Figg; Christopher J Schofield
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism.
The Journal of biological chemistry 2009;284(39):26831-8.
2009: Stephen T Pisle; William D Figg
Antiandrogens in the 21st century.
Cancer biology & therapy 2009;8(17):1611.
2009: Lokesh Jain; Craig A Vargo; Romano Danesi; Tristan Sissung; Douglas K Price; David Venzon; Jürgen Venitz; William D Figg
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.
Molecular cancer therapeutics 2009;8(9):2496-508.
2009: Lorelei A Mucci; Jennifer R Stark; William D Figg; Fredrick Schumacher; Haojie Li; Miyako Abe; Kristen Hennessy; Meir J Stampfer; John Michael Gaziano; Jing Ma; Philip W Kantoff
Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
International journal of cancer. Journal international du cancer 2009;125(5):1143-6.
2009: Yang-Min Ning; William D Figg; William L Dahut
Reversal of docetaxel resistance with bevacizumab and thalidomide.
Clinical genitourinary cancer 2009;7(2):E37-8.
2009: Andrea L Russo; Kimberly Jedlicka; Meredith Wernick; Debbie McNally; Melissa Kirk; Mary Sproull; Sharon Smith; Uma Shankavaram; Aradhana Kaushal; William D Figg; William Dahut; Deborah Citrin; Donald P Bottaro; Paul S Albert; Philip J Tofilon; Kevin A Camphausen
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4292-8.
2009: Bevin C English; Douglas K Price; William D Figg
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
Cancer biology & therapy 2009;8(13):1214-25.
2009: William L Dahut; Jeanny B Aragon-Ching; Sukyung Woo; Tanyifor M Tohnya; James L Gulley; Philip M Arlen; John J Wright; Jurgen Ventiz; William D Figg
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Journal of clinical pharmacology 2009;49(6):650-60.
2009: Jeanny B Aragon-Ching; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Seth M Steinberg; David Draper; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
BJU international 2009;103(12):1636-40.
2009: Christina Therapontos; Lynda Erskine; Erin R Gardner; William D Figg; Neil Vargesson
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(21):8573-8.
2009: William D Figg; Maha Hussain; James L Gulley; Philip M Arlen; Jeanny B Aragon-Ching; Daniel P Petrylak; Celestia S Higano; Seth M Steinberg; Gurkamal S Chatta; Howard L Parnes; John J Wright; Oliver Sartor; William L Dahut
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
The Journal of urology 2009;181(3):1104-13; discussion 1113.
2009: Sukyung Woo; Erin R Gardner; Xiaohong Chen; Sandra B Ockers; Caitlin E Baum; Tristan Sissung; Douglas K Price; Robin Frye; Richard L Piekarz; Susan E Bates; William D Figg
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1496-503.
2009: Nilofer S Azad; Jeanny B Aragon-Ching; William L Dahut; Martin Gutierrez; William D Figg; Lokesh Jain; Seth M Steinberg; Maria L Turner; Elise C Kohn; Heidi H Kong
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1411-6.
2009: Jeanny B Aragon-Ching; Yang-Min Ning; Clara C Chen; Lea Latham; Jean-Pierre Guadagnini; James L Gulley; Philip M Arlen; John J Wright; Howard L Parnes; William D Figg; William L Dahut
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer investigation 2009;27(2):221-6.
2009: Matthew Danish; Erin R Gardner; Xiaohong Chen; William D Figg
Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(3):355-9.
2009: Erin R Gardner; Nicola F Smith; William D Figg; Alex Sparreboom
Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
Journal of experimental & clinical cancer research : CR 2009;28():99.
2008: Shian-Ying Sung; Chia-Ling Hsieh; Andrew Law; Haiyen E Zhau; Sen Pathak; Asha S Multani; Sharon Lim; Ilsa M Coleman; Li-Chin Wu; William D Figg; William L Dahut; Peter Nelson; Jae K Lee; Mahul B Amin; Robert Lyles; Peter A J Johnstone; Fray F Marshall; Leland W K Chung
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.
Cancer research 2008;68(23):9996-10003.
2008: Erin R Gardner; Christoph M Ahlers; Suneet Shukla; Tristan Sissung; Sandra B Ockers; Douglas K Price; Akinobu Hamada; Robert W Robey; Seth M Steinberg; Suresh V Ambudkar; William L Dahut; William D Figg
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
BJU international 2008;102(11):1694-9.
2008: Giuseppe Di Lorenzo; William D Figg; Sophie D Fossa; Vincenzo Mirone; Riccardo Autorino; Nicola Longo; Ciro Imbimbo; Sisto Perdonà; Antonio Giordano; Mario Giuliano; Roberto Labianca; Sabino De Placido
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
European urology 2008;54(5):1089-94.
2008: William D Figg
The Pharm.D. investigator in clinical pharmacology: supply and demand.
Clinical pharmacology and therapeutics 2008;84(4):526-9.
2008: Cindy H Chau; Olivier Rixe; howard mcleod; William D Figg
Validation of analytic methods for biomarkers used in drug development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(19):5967-76.
2008: James L Gulley; Jeanny B Aragon-Ching; Seth M Steinberg; Maha Hussain; Oliver Sartor; Celestia S Higano; Daniel P Petrylak; Gurkamal S Chatta; Philip M Arlen; William D Figg; William L Dahut
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
The Journal of urology 2008;180(4):1432-7; discussion 1437.
2008: Cindy H Chau; Weixin Wang; William D Figg
Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis.
Cancer biology & therapy 2008;7(9):1386-7.
2008: Yun Ge; Jung S Byun; Paola De Luca; Geraldine Gueron; Idalia M Yabe; Sara G Sadiq-Ali; William D Figg; Jesse Quintero; Cynthia M Haggerty; Quentin Q Li; Adriana De Siervi; Kevin Gardner
Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.
Molecular pharmacology 2008;74(3):872-83.
2008: Nima Sharifi; Akinobu Hamada; Tristan Sissung; Romano Danesi; David Venzon; Caitlin Baum; James L Gulley; Douglas K Price; William L Dahut; William D Figg
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
BJU international 2008;102(5):617-21.
2008: Robert J Miles; Douglas K Price; William D Figg
Temporal-mediated FGFR1 independence: implications for targeting candidate molecules in prostate cancer.
Cancer biology & therapy 2008;7(8):1180-1.
2008: Nima Sharifi; William L Dahut; William D Figg
The genetics of castration-resistant prostate cancer: what can the germline tell us?
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(15):4691-3.
2008: Tristan Sissung; Caitlin E Baum; John Deeken; Douglas K Price; Jeanny Aragon-Ching; Seth M Steinberg; William Dahut; Alex Sparreboom; William D Figg
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4543-9.
2008: Weixin Wang; William D Figg
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Cancer biology & therapy 2008;7(7):1004-5.
2008: Erin R Gardner; William L Dahut; Charity D Scripture; Jacquin Jones; Jeanny B Aragon-Ching; Neil Desai; Michael J Hawkins; Alex Sparreboom; William D Figg
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4200-5.
2008: William D Figg; Cindy H Chau; Richard Okita; Peter Preusch; Timothy S Tracy; howard mcleod; Michael Reed; John A Pieper; Daren Knoell; Ken Miller; Marilyn Speedie; Robert Blouin; Patricia Kroboth; Mary Anne Koda-Kimble; Palmer Taylor; Jordan Cohen; Kathy Giacomini
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research.
Pharmacotherapy 2008;28(7):821-33.
2008: Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3312-8.
2008: Philip M Arlen; Fernando Bianco; William L Dahut; Anthony V D'Amico; William D Figg; Stephen J Freedland; James L Gulley; Philip W Kantoff; Michael W Kattan; Andrew Lee; Meredith M Regan; Oliver Sartor
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
The Journal of urology 2008;179(6):2181-5; discussion 2185-6.
2008: Nicola F Smith; Sharyn D Baker; Frank J Gonzalez; J W Harris; William D Figg; Alex Sparreboom
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
British journal of cancer 2008;98(10):1630-2.
2008: Rui Gao; Douglas K Price; Tristan Sissung; Eddie Reed; William D Figg
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.
Molecular cancer therapeutics 2008;7(5):1246-50.
2008: Ashraful Hoque; Phyllis Goodman; Christine B Ambrosone; William D Figg; Douglas K Price; William Kopp; Xifeng Wu; Jeffrey Conroy; Teresa A Lehman; Regina M Santella
Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial.
Urology 2008;71(5):967-70.
2008: Xiaohong Chen; Erin R Gardner; Douglas K Price; William D Figg
Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis.
Journal of chromatographic science 2008;46(4):356-61.
2008: Xiaohong Chen; Erin R Gardner; William D Figg
Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;865(1-2):153-8.
2008: Haiqing Li; Valentina Raia; Francesco Bertolini; Douglas K Price; William D Figg
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
BJU international 2008;101(7):884-8.
2008: Matthew Danish; Tristan Sissung; Douglas K Price; William D Figg
Genetic stability of tumor microenvironment.
Cancer biology & therapy 2008;7(3):331-2.
2008: Howard I Scher; Susan Halabi; Ian Tannock; Michael J Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia S Higano; Glenn J Bubley; Robert Dreicer; Daniel P Petrylak; Philip W Kantoff; Ethan Basch; W Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1148-59.
2008: Erin R Gardner; Alex Sparreboom; Jaap Verweij; William D Figg
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib.
Cancer biology & therapy 2008;7(3):412-5.
2008: Erin R Gardner; William Dahut; William D Figg
Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;862(1-2):213-8.
2008: Nima Sharifi; William L Dahut; William D Figg
Secondary hormonal therapy for prostate cancer: what lies on the horizon?
BJU international 2008;101(3):271-4.
2008: Lokesh Jain; Erin R Gardner; Jürgen Venitz; William Dahut; William D Figg
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
Journal of pharmaceutical and biomedical analysis 2008;46(2):362-7.
2008: Tristan Sissung; Erin R Gardner; Rui Gao; William D Figg
Pharmacogenetics of membrane transporters: a review of current approaches.
Methods in molecular biology (Clifton, N.J.) 2008;448():41-62.
2008: Tristan Sissung; Romano Danesi; Douglas K Price; Seth M Steinberg; Ronald de Wit; Muhammad Zahid; Nilesh Gaikwad; Ercole Cavalieri; William L Dahut; Dan L Sackett; William D Figg; Alex Sparreboom
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Molecular cancer therapeutics 2008;7(1):19-26.
2008: William L Dahut; Charity Scripture; Edwin M Posadas; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Yunkai Yu; Liang Cao; Seth M Steinberg; Jeanny B Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):209-14.
2008: David S Schrump; Maria R Fischette; Dao Nguyen; Ming Zhao; Xinmin Li; Tricia F Kunst; Ana Hancox; Julie A Hong; G Aaron Chen; Evgeny Kruchin; John J Wright; Douglas R Rosing; Alex Sparreboom; William D Figg; Seth M Steinberg
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):188-98.
2007: Howard A Fine; Lyndon Kim; Paul S Albert; J Paul Duic; Hilary Ma; Wei Zhang; Tanyifor Tohnya; William D Figg; Cheryl Royce
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(23):7101-6.
2007: Jeanny B Aragon-Ching; John Gillespie; Douglas K Price; Rodrigo F Chuaqui; Jaime Rodriguez-Canales; Seth M Steinberg; William L Dahut; William D Figg
Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer.
BJU international 2007;100(6):1245-8.
2007: Xiaohong Chen; Erin R Gardner; Martin Gutierrez; Shivaani Kummar; William D Figg
Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;858(1-2):302-6.
2007: Giuseppe Di Lorenzo; Riccardo Autorino; Sisto Perdonà; Michele De Laurentiis; Massimo D'Armiento; Giuseppe Cancello; Vincenzo Mirone; Ciro Imbimbo; Nicola Longo; Vincenzo Altieri; Giampaolo Tortora; William D Figg; Sabino De Placido
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
European urology 2007;52(4):1020-7.
2007: Shivaani Kummar; Martin Gutierrez; Erin R Gardner; Erin Donovan; Kyunghwa Hwang; Eun Joo Chung; Min-Jung Lee; Kim Maynard; Mikhail Kalnitskiy; Alice Chen; Giovanni Melillo; Qin C Ryan; BA Conley; William D Figg; Jane Trepel; James Zwiebel; James Doroshow; Anthony J Murgo
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5411-7.
2007: Nima Sharifi; William D Figg
Androgen receptor modulation: lessons learned from beyond the prostate.
Cancer biology & therapy 2007;6(9):1358-9.
2007: Joell J Gills; Jaclyn LoPiccolo; Junji Tsurutani; Robert H Shoemaker; Carolyn J M Best; Mones Abu-Asab; Jennifer Borojerdi; Noel A Warfel; Erin R Gardner; Matthew Danish; M Christine Hollander; Shigeru Kawabata; Maria Tsokos; William D Figg; Patricia S Steeg; Phillip A Dennis
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5183-94.
2007: Jacob N Beverage; Tristan Sissung; Amy M Sion; Romano Danesi; William D Figg
CYP2D6 polymorphisms and the impact on tamoxifen therapy.
Journal of pharmaceutical sciences 2007;96(9):2224-31.
2007: Akinobu Hamada; Romano Danesi; Douglas K Price; Tristan Sissung; Cindy Chau; David Venzon; Alex Sparreboom; William L Dahut; William D Figg
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Urology 2007;70(2):217-20.
2007: Nehal J Lakhani; Alex Sparreboom; Xia Xu; Timothy D Veenstra; Jürgen Venitz; William L Dahut; William D Figg
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.
Journal of pharmaceutical sciences 2007;96(7):1821-31.
2007: Jeanny B Aragon-Ching; Haiqing Li; Erin R Gardner; William D Figg
Thalidomide analogues as anticancer drugs.
Recent patents on anti-cancer drug discovery 2007;2(2):167-74.
2007: Suman Lal; Zee-Wan Wong; Srinivasa Rao Jada; Xiaoqiang Xiang; Xiao Chen Shu; Peter Cher Siang Ang; William D Figg; Edmund Jd Lee; Balram Chowbay
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.
Pharmacogenomics 2007;8(6):567-75.
2007: Haiqing Li; Douglas K Price; William D Figg
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer.
Anti-cancer drugs 2007;18(5):563-8.
2007: William D Figg; Haiqing Li; Tristan Sissung; Avi S Retter; Shenhong Wu; James L Gulley; Philip M Arlen; John J Wright; Howard L Parnes; Kathy Fedenko; Lea Latham; Seth M Steinberg; Elizabeth Jones; Clara Chen; William Dahut
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
BJU international 2007;99(5):1047-55.
2007: Ivana Gojo; Anchalee Jiemjit; Jane Trepel; Alex Sparreboom; William D Figg; Sandra Rollins; Michael L Tidwell; Jacqueline Greer; Eun Joo Chung; Min-Jung Lee; Steven D Gore; Edward A Sausville; James Zwiebel; Judith E Karp
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood 2007;109(7):2781-90.
2007: Tania Al-Chalabi; William D Figg
Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients.
Cancer biology & therapy 2007;6(3):318-9.
2007: Shenhong L Wu; Elizabeth Jones; James L Gulley; Philip M Arlen; Clara C Chen; William D Figg; William L Dahut
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
BJU international 2007;99(3):525-8.
2007: John F Deeken; William D Figg; Susan E Bates; Alex Sparreboom
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Anti-cancer drugs 2007;18(2):111-26.
2007: Giuseppe Di Lorenzo; Riccardo Autorino; William D Figg; Sabino De Placido
Hormone-refractory prostate cancer: where are we going?
Drugs 2007;67(8):1109-24.
2007: Nicola F Smith; Sharon Marsh; Tiffany J Scott-Horton; A Hamada; Stephan Mielke; Klaus Mross; William D Figg; Jaap Verweij; howard mcleod; Alex Sparreboom
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
Clinical pharmacology and therapeutics 2007;81(1):76-82.
2006: Yun Ge; Idalia Montano; Gabriella Rustici; Wendy J Freebern; Cynthia M Haggerty; Wenwu Cui; Damaris Ponciano-Jackson; Gadisetti V R Chandramouli; Erin R Gardner; William D Figg; Mones Abu-Asab; Maria Tsokos; Sharon H Jackson; Kevin Gardner
Selective leukemic-cell killing by a novel functional class of thalidomide analogs.
Blood 2006;108(13):4126-35.
2006: Sandra Ockers; Douglas K Price; William D Figg
DNA microarrays: tissue removal and processing affects gene expression.
Cancer biology & therapy 2006;5(12):1608-9.
2006: Erika K Smith; Douglas K Price; William D Figg
Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation.
Cancer biology & therapy 2006;5(11):1443-4.
2006: Tristan Sissung; Klaus Mross; Seth M Steinberg; Dirk Behringer; William D Figg; Alex Sparreboom; Stephan Mielke
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2893-6.
2006: David S Schrump; Maria R Fischette; Dao Nguyen; Ming Zhao; Xinmin Li; Tricia F Kunst; Ana Hancox; Julie A Hong; G Aaron Chen; Vitaliy Pishchik; William D Figg; Anthony J Murgo; Seth M Steinberg
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5777-85.
2006: William D Figg; Sandra Ockers
Prostate cancer - 6th International Congress.
IDrugs : the investigational drugs journal 2006;9(10):675-8.
2006: Howard L Parnes; William D Figg
Chemoprevention in prostate cancer.
Pharmacotherapy 2006;26(10):1533; author reply 1533.
2006: Lokesh Jain; Jürgen Venitz; William D Figg
Randomized discontinuation trial of sorafenib (BAY 43-9006).
Cancer biology & therapy 2006;5(10):1270-2.
2006: Jacob N Beverage; William D Figg
The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator.
Cancer biology & therapy 2006;5(9):1094-5.
2006: Nehal J Lakhani; Alex Sparreboom; Jürgen Venitz; William L Dahut; William D Figg
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
Anti-cancer drugs 2006;17(8):977-83.
2006: Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin C Ryan; Ivana Gojo; Jürgen Venitz; William D Figg; Alex Sparreboom
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Investigational new drugs 2006;24(5):367-75.
2006: Amy M Sion; William D Figg
Lysyl oxidase (LOX) and hypoxia-induced metastases.
Cancer biology & therapy 2006;5(8):909-11.
2006: Erin R Lepper; Nicola F Smith; Michael C Cox; Charity D Scripture; William D Figg
Thalidomide metabolism and hydrolysis: mechanisms and implications.
Current drug metabolism 2006;7(6):677-85.
2006: Michael C Cox; Jennifer Low; James Lee; Janice M Walshe; Neelima Denduluri; Arlene Berman; Matthew G Permenter; William P Petros; Douglas K Price; William D Figg; Alex Sparreboom; Sandra M Swain
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4636-40.
2006: Erin R Gardner; Herman Burger; Ron van Schaik; Allan T van Oosterom; Ernst A de Bruijn; Gunther Guetens; Hans Prenen; Floris A de Jong; Sharyn D Baker; Susan E Bates; William D Figg; Jaap Verweij; Alex Sparreboom; Kees Nooter
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Clinical pharmacology and therapeutics 2006;80(2):192-201.
2006: Sylvia S W Ng; Alex Sparreboom; Yuval Shaked; Christina Lee; Shan Man; Neil Desai; Patrick Soon-Shiong; William D Figg; Robert S Kerbel
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4331-8.
2006: James L Gulley; William D Figg; William Dahut
Even more cost savings?
Journal of oncology practice / American Society of Clinical Oncology 2006;2(4):202.
2006: William D Figg; Cindy H Chau
Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics.
Cancer biology & therapy 2006;5(7):840-1.
2006: Charity D Scripture; William D Figg
Drug interactions in cancer therapy.
Nature reviews. Cancer 2006;6(7):546-58.
2006: Noel A Warfel; Erin R Lepper; Chunyu Zhang; William D Figg; Phillip A Dennis
Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3502-9.
2006: William D Figg; Lara Dunn; David J Liewehr; Seth M Steinberg; Paul W Thurman; J Carl Barrett; Julian Birkinshaw
Scientific collaboration results in higher citation rates of published articles.
Pharmacotherapy 2006;26(6):759-67.
2006: Michael C Cox; William L Dahut; William D Figg
The use of thalidomide in androgen-independent prostate cancer.
Urologic oncology 2006;24(3):246-9.
2006: Charity D Scripture; William D Figg; Alex Sparreboom
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives.
Current neuropharmacology 2006;4(2):165-72.
2006: Alex Sparreboom; William D Figg
Identifying sources of interindividual pharmacokinetic variability with population modeling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):1951-3.
2006: Christoph M Ahlers; William D Figg
ETS-TMPRSS2 fusion gene products in prostate cancer.
Cancer biology & therapy 2006;5(3):254-5.
2006: Tristan Sissung; Douglas K Price; Alex Sparreboom; William D Figg
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.
Molecular cancer research : MCR 2006;4(3):135-50.
2006: Arun S Singh; Gordon R Macpherson; Douglas K Price; Daniel Schimel; William D Figg
Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Oncology reports 2006;15(3):519-24.
2006: Nicola F Smith; William D Figg; Alex Sparreboom
Pharmacogenetics of irinotecan metabolism and transport: an update.
Toxicology in vitro : an international journal published in association with BIBRA 2006;20(2):163-75.
2006: Charity D Scripture; William D Figg; Alex Sparreboom
The role of drug-metabolising enzymes in clinical responses to chemotherapy.
Expert opinion on drug metabolism & toxicology 2006;2(1):17-25.
2006: Milin R Acharya; Alex Sparreboom; Edward A Sausville; BA Conley; James Doroshow; Jürgen Venitz; William D Figg
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer chemotherapy and pharmacology 2006;57(3):275-81.
2006: Kyunghwa Hwang; Charity D Scripture; Martin Gutierrez; Shivaani Kummar; William D Figg; Alex Sparreboom
Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;830(1):35-40.
2006: Erin R Gardner; Chi-Ting Liau; Zyting E Chu; William D Figg; Alex Sparreboom
Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2006;20(14):2170-4.
2006: William D Figg
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
Clinical pharmacology and therapeutics 2006;79(1):1-8.
2006: William L Dahut; Nehal J Lakhani; James L Gulley; Philip M Arlen; Elise C Kohn; Herb Kotz; Debbie McNally; Allyson L Parr; Diana Nguyen; Sherry X Yang; Seth M Steinberg; Jürgen Venitz; Alex Sparreboom; William D Figg
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer biology & therapy 2006;5(1):22-7.
2006: Flora Rozhansky; Ming-Hui Chen; Michael C Cox; William Dahut; William D Figg; Anthony V D'Amico
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
Cancer 2006;106(1):63-7.
2005: Ritchie L Longoria; Michael C Cox; William D Figg
Antiangiogenesis: a possible treatment option for prostate cancer?
Clinical genitourinary cancer 2005;4(3):197-202.
2005: Frederick A Luzzio; Damien Y Duveau; Erin R Lepper; William D Figg
Synthesis of racemic cis-5-hydroxy-3-phthalimidoglutarimide. A metabolite of thalidomide isolated from human plasma.
The Journal of organic chemistry 2005;70(24):10117-20.
2005: Nima Sharifi; William L Dahut; Seth M Steinberg; William D Figg; Christopher Tarassoff; Philip M Arlen; James L Gulley
A retrospective study of the time to clinical endpoints for advanced prostate cancer.
BJU international 2005;96(7):985-9.
2005: Cindy H Chau; Matthew G Permenter; Seth M Steinberg; Avi S Retter; William L Dahut; Douglas K Price; William D Figg
Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.
Cancer biology & therapy 2005;4(11):1222-5.
2005: Erin R Lepper; Sharyn D Baker; Matthew G Permenter; Nicole Ries; Ron van Schaik; Paul W Schenk; Douglas K Price; Danielle Ahn; Nicola F Smith; George Cusatis; Roxann G Ingersoll; Susan E Bates; Ron H J Mathijssen; Jaap Verweij; William D Figg; Alex Sparreboom
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7398-404.
2005: Nicola F Smith; William D Figg; Alex Sparreboom
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.
Expert opinion on drug metabolism & toxicology 2005;1(3):429-45.
2005: Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Molecular alterations in primary prostate cancer after androgen ablation therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6823-34.
2005: Charity D Scripture; Alex Sparreboom; William D Figg
Modulation of cytochrome P450 activity: implications for cancer therapy.
The lancet oncology 2005;6(10):780-9.
2005: Edwin M Posadas; James L Gulley; Philip M Arlen; Alisa Trout; Howard L Parnes; John Wright; Min-Jung Lee; Eun Joo Chung; Jane Trepel; Alex Sparreboom; Clara Chen; Elizabeth Jones; Seth M Steinberg; Andrew Daniels; William D Figg; William L Dahut
A phase II study of perifosine in androgen independent prostate cancer.
Cancer biology & therapy 2005;4(10):1133-7.
2005: Milin R Acharya; Alex Sparreboom; Jürgen Venitz; William D Figg
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Molecular pharmacology 2005;68(4):917-32.
2005: Anthony V D'Amico; Ming-Hui Chen; Michael C Cox; William Dahut; William D Figg
Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
Urology 2005;66(3):571-6.
2005: Arun S Singh; William D Figg
In vivo models of prostate cancer metastasis to bone.
The Journal of urology 2005;174(3):820-6.
2005: Nicola F Smith; Milin R Acharya; Neil Desai; William D Figg; Alex Sparreboom
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.
Cancer biology & therapy 2005;4(8):815-8.
2005: Victoria L Tkacz; Tanyifor M Tohnya; William D Figg
Cyclooxygenase-2 and angiogenesis in prostate cancer.
Cancer biology & therapy 2005;4(8):813-4.
2005: Michael C Cox; Charity D Scripture; William D Figg
Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Expert review of anticancer therapy 2005;5(4):605-11.
2005: Qin C Ryan; Donna Headlee; Milin R Acharya; Alex Sparreboom; Jane Trepel; Joseph Ye; William D Figg; Kyunghwa Hwang; Eun Joo Chung; Anthony J Murgo; Giovanni Melillo; Yusri Elsayed; Manish Monga; Mikhail Kalnitskiy; James Zwiebel; Edward A Sausville
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3912-22.
2005: Charity D Scripture; William D Figg; Alex Sparreboom
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
Therapeutics and clinical risk management 2005;1(2):107-14.
2005: Alex Sparreboom; Charity D Scripture; Vuong Trieu; Paul J Williams; Tapas De; Andrew Yang; Bridget Beals; William D Figg; Michael Hawkins; Neil Desai
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4136-43.
2005: Alex Sparreboom; Walter J Loos; Herman Burger; Tristan Sissung; Jaap Verweij; William D Figg; Kees Nooter; Hans Gelderblom
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer biology & therapy 2005;4(6):650-8.
2005: James F Pingpank; Steven Libutti; Richard Chang; Bradford J Wood; Ziv Neeman; Anthony W Kam; William D Figg; Souping Zhai; Tatiana Beresneva; Geoffrey D Seidel; H Richard Alexander
Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3465-74.
2005: Charity D Scripture; Janos Szebeni; Walter J Loos; William D Figg; Alex Sparreboom
Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Cancer biology & therapy 2005;4(5):555-60.
2005: Michael C Cox; Matthew G Permenter; William D Figg
Angiogenesis and prostate cancer: important laboratory and clinical findings.
Current oncology reports 2005;7(3):215-9.
2005: James L Gulley; William D Figg; Seth M Steinberg; Jane Carter; Oliver Sartor; Celestia S Higano; Daniel P Petrylak; Gurkamal S Chatta; Maha Hussain; William L Dahut
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
The Journal of urology 2005;173(5):1567-71.
2005: Eiichi Fuse; Takashi Kuwabara; Alex Sparreboom; Edward A Sausville; William D Figg
Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
Journal of clinical pharmacology 2005;45(4):394-403.
2005: Erin R Lepper; Kees Nooter; Jaap Verweij; Milin R Acharya; William D Figg; Alex Sparreboom
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Pharmacogenomics 2005;6(2):115-38.
2005: William D Figg; Yinong Liu; Philip M Arlen; James L Gulley; Seth M Steinberg; David J Liewehr; Michael C Cox; Suoping Zhai; Serge Cremers; Allyson L Parr; Xiaowei Yang; Clara C Chen; Elizabeth Jones; William L Dahut
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
The Journal of urology 2005;173(3):790-6.
2005: Arun S Singh; Cindy H Chau; Douglas K Price; William D Figg
Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer.
Nature clinical practice. Urology 2005;2(2):101-7.
2005: Cindy H Chau; William D Figg
Molecular and phenotypic heterogeneity of metastatic prostate cancer.
Cancer biology & therapy 2005;4(2):166-7.
2005: Nehal J Lakhani; Erin R Lepper; Alex Sparreboom; William L Dahut; Jürgen Venitz; William D Figg
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2005;19(9):1176-82.
2005: Sharyn D Baker; Jing Li; Albert J ten Tije; William D Figg; Wilfried J Graveland; Jaap Verweij; Alex Sparreboom
Relationship of systemic exposure to unbound docetaxel and neutropenia.
Clinical pharmacology and therapeutics 2005;77(1):43-53.
2004: Sylvia S W Ng; William D Figg
Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy.
Cancer biology & therapy 2004;3(12):1212-3.
2004: Gordon R Macpherson; Arun S Singh; Charles L Bennett; David J Venzon; David J Liewehr; Michael E Franks; William L Dahut; Philip W Kantoff; Douglas K Price; William D Figg
Genotyping and functional analysis of the D104N variant of human endostatin.
Cancer biology & therapy 2004;3(12):1298-303.
2004: William D Figg; Michael E Franks; David Venzon; Paul H Duray; Michael C Cox; W Marston Linehan; W Van Bingham; James A Eastham; Eddie Reed; Oliver Sartor
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
World journal of urology 2004;22(6):425-30.
2004: Tanyifor M Tohnya; Kyunghwa Hwang; Erin R Lepper; Howard A Fine; William L Dahut; Jürgen Venitz; Alex Sparreboom; William D Figg
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;811(2):135-41.
2004: Ron H J Mathijssen; Floris A de Jong; Ron van Schaik; Erin R Lepper; Lena E Friberg; Trinet Rietveld; Peter de Bruijn; Wilfried J Graveland; William D Figg; Jaap Verweij; Alex Sparreboom
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Journal of the National Cancer Institute 2004;96(21):1585-92.
2004: Tanyifor M Tohnya; William D Figg
Immunomodulation of multiple myeloma.
Cancer biology & therapy 2004;3(11):1060-1.
2004: Alex Sparreboom; Huachen Chen; Milin R Acharya; Adrian M Senderowicz; Richard A Messmann; Takashi Kuwabara; David J Venzon; Anthony J Murgo; Donna Headlee; Edward A Sausville; William D Figg
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6840-6.
2004: Kyunghwa Hwang; Richard L Piekarz; Susan E Bates; William D Figg; Alex Sparreboom
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;809(1):81-6.
2004: Antoinette R Tan; Xiaowei Yang; Arlene Berman; Suoping Zhai; Alex Sparreboom; Allyson L Parr; Catherine Chow; Jaime Brahim; Seth M Steinberg; William D Figg; Sandra M Swain
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5038-47.
2004: Luca Paoluzzi; Arun S Singh; Douglas K Price; Romano Danesi; Ron H J Mathijssen; Jaap Verweij; William D Figg; Alex Sparreboom
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Journal of clinical pharmacology 2004;44(8):854-60.
2004: Antoinette R Tan; Xiaowei Yang; Stephen M Hewitt; Arlene Berman; Erin R Lepper; Alex Sparreboom; Allyson L Parr; William D Figg; Catherine Chow; Seth M Steinberg; Stephen L Bacharach; Millie Whatley; Jorge Carrasquillo; Jaime Brahim; Seth A Ettenberg; Stan Lipkowitz; Sandra M Swain
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3080-90.
2004: Milin R Acharya; William D Figg
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
Cancer biology & therapy 2004;3(8):719-20.
2004: Milin R Acharya; Sharyn D Baker; Jaap Verweij; William D Figg; Alex Sparreboom
Determination of fraction unbound docetaxel using microequilibrium dialysis.
Analytical biochemistry 2004;331(1):192-4.
2004: Susan E Bates; Susan Bakke; Min Kang; Robert W Robey; Suoping Zhai; Paul Thambi; Clara C Chen; Sheela Patil; Tom Smith; Seth M Steinberg; Maria Merino; Barry Goldspiel; Beverly Meadows; Wilfred D Stein; Peter Choyke; FRANK BALIS; William D Figg; Tito Fojo
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4724-33.
2004: Erin R Lepper; J Kevin Hicks; Jaap Verweij; Suoping Zhai; William D Figg; Alex Sparreboom
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):305-10.
2004: Nehal J Lakhani; Alex Sparreboom; William L Dahut; Jürgen Venitz; William D Figg
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):289-93.
2004: William L Dahut; James L Gulley; Philip M Arlen; Yinong Liu; Kathy Fedenko; Seth M Steinberg; John J Wright; Howard L Parnes; Clara C Chen; Elizabeth Jones; Catherine E Parker; W Marston Linehan; William D Figg
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2532-9.
2004: Luca Paoluzzi; William D Figg
Histone deacetylase inhibitors are potent radiation protectants.
Cancer biology & therapy 2004;3(7):612-3.
2004: Sylvia S W Ng; Gordon R Macpherson; Michael Gütschow; Kurt Eger; William D Figg
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4192-7.
2004: Alex Sparreboom; Michael C Cox; Milin R Acharya; William D Figg
Herbal remedies in the United States: potential adverse interactions with anticancer agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2489-503.
2004: Tanyifor M Tohnya; Sonia Kim; Howard A Fine; Lara Dunn; William D Figg; Alex Sparreboom
Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;805(1):135-40.
2004: Milin R Acharya; Jürgen Venitz; William D Figg; Alex Sparreboom
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2004;7(3):195-208.
2004: Gordon R Macpherson; William D Figg
Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade.
Cancer biology & therapy 2004;3(6):503-4.
2004: Douglas K Price; William D Figg
hTert-immortalized endothelial cells: an important new research tool.
Cell cycle (Georgetown, Tex.) 2004;3(6):789.
2004: Michael E Franks; Gordon R Macpherson; William D Figg
Thalidomide.
Lancet 2004;363(9423):1802-11.
2004: Kyunghwa Hwang; Milin R Acharya; Edward A Sausville; Suoping Zhai; Eunhee W Woo; Jürgen Venitz; William D Figg; Alex Sparreboom
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):289-94.
2004: Douglas K Price; William D Figg
Mutations in the EGFR: the importance of genotyping.
Cancer biology & therapy 2004;3(5):434-5.
2004: Erin R Lepper; Sylvia S W Ng; Michael Gütschow; Michael Weiss; Sunna Hauschildt; Thomas K Hecker; Frederick A Luzzio; Kurt Eger; William D Figg
Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.
Journal of medicinal chemistry 2004;47(9):2219-27.
2004: Tanyifor M Tohnya; Sylvia S W Ng; William L Dahut; John J Wright; Philip M Arlen; James L Gulley; Catherine Parker; Jerome B Zeldis; William D Figg
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Clinical prostate cancer 2004;2(4):241-3.
2004: Michael C Cox; William D Figg; Paul W Thurman
No rational theory for drug pricing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):962-3.
2004: Donald M McDonald; Beverly A Teicher; William Stetler-Stevenson; Sylvia S W Ng; William D Figg; Judah Folkman; Douglas Hanahan; Robert Auerbach; Michael O'Reilly; Roy Herbst; David A Cheresh; Michael S Gordon; Alexander Eggermont; Steven Libutti
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(2):161-75.
2004: Arun Singh; William D Figg
Upregulation of the androgen receptor during prostate cancer progression.
Cancer biology & therapy 2004;3(3):284-5.
2004: Sylvia S W Ng; William D Figg; Alex Sparreboom
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
Cancer research 2004;64(3):821-4.
2004: Linda W Chan; Marsha A Moses; Elizabeth Goley; Mary Sproull; Thierry Muanza; C Norman Coleman; William D Figg; Paul S Albert; Cynthia Ménard; Kevin A Camphausen
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):499-506.
2004: Douglas K Price; Michael E Franks; William D Figg
Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism.
The Journal of urology 2004;171(2 Pt 2):S45-9; discussion S49.
2003: Avi S Retter; William D Figg; William L Dahut
The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer.
Clinical prostate cancer 2003;2(3):153-9.
2003: Michael E Franks; Gordon R Macpherson; Erin R Lepper; William D Figg; Alex Sparreboom
New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(6):301-12.
2003: Nehal J Lakhani; Jürgen Venitz; William D Figg; Alex Sparreboom
Pharmacogenetics of estrogen metabolism and transport in relation to cancer.
Current drug metabolism 2003;4(6):505-13.
2003: Mahrukh M Hussain; Herb Kotz; Lori M Minasian; Ahalya Premkumar; Gisele Sarosy; Eddie Reed; Suoping Zhai; Seth M Steinberg; Miranda Raggio; Vyta Kulpa Oliver; William D Figg; Elise C Kohn
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4356-63.
2003: William D Figg; Michael C Cox
Pharmacy education: back to the basics?
Pharmacotherapy 2003;23(11):1381-90.
2003: Albert J ten Tije; Walter J Loos; Jaap Verweij; Sharyn D Baker; Kimberly Dinh; William D Figg; Alex Sparreboom
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
Clinical pharmacology and therapeutics 2003;74(5):509-10.
2003: Erin R Lepper; Sandra M Swain; Antoinette R Tan; William D Figg; Alex Sparreboom
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;796(1):181-8.
2003: MICHELLE RUDEK-RENAUT; Kenneth S. Bauer; Richard M Lush; Sherman F Stinson; Adrian M Senderowicz; Donna Headlee; Arbuck Susan; Michael C Cox; Anthony J Murgo; Edward A Sausville; William D Figg
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
The Annals of pharmacotherapy 2003;37(10):1369-74.
2003: MICHELLE RUDEK-RENAUT; Jürgen Venitz; Yuichi Ando; Eddie Reed; James M Pluda; William D Figg
Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.
Journal of clinical pharmacology 2003;43(10):1124-35.
2003: Sylvia S W Ng; William D Figg
Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice.
Anticancer research 2003;23(5A):3585-90.
2003: Gordon R Macpherson; Sylvia S W Ng; Siiri L Forbes; Giovanni Melillo; Tatiana S Karpova; James McNally; Thomas P Conrads; Timothy D Veenstra; Alfredo Martinez; Frank Cuttitta; Douglas K Price; William D Figg
Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.
Molecular cancer therapeutics 2003;2(9):845-54.
2003: Maureen D Passaro; Johann Piquion; Nancy Mullen; Dorette Sutherland; Suoping Zhai; William D Figg; Richard P Blye; Lynnette K Nieman
Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women.
Human reproduction (Oxford, England) 2003;18(9):1820-7.
2003: Frederick A Luzzio; Alexander V Mayorov; Sylvia S W Ng; Erwin A Kruger; William D Figg
Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
Journal of medicinal chemistry 2003;46(18):3793-9.
2003: Gordon R Macpherson; Michael E Franks; Andrada Tomoaia-Cotisel; Yuichi Ando; Douglas K Price; William D Figg
Current status of thalidomide and its role in the treatment of metastatic prostate cancer.
Critical reviews in oncology/hematology 2003;46 Suppl():S49-57.
2003: Sylvia S W Ng; Michael Gütschow; Michael Weiss; Sunna Hauschildt; Uwe Teubert; Thomas K Hecker; Frederick A Luzzio; Erwin A Kruger; Kurt Eger; William D Figg
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Cancer research 2003;63(12):3189-94.
2003: Howard A Fine; Patrick Y Wen; Elizabeth A Maher; Elene Viscosi; Tracy Batchelor; Nehal J Lakhani; William D Figg; Benjamin Purow; Craig B Borkowf
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(12):2299-304.
2003: Alex Sparreboom; Romano Danesi; Yuichi Ando; Juliana Chan; William D Figg
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(2):71-84.
2003: Karen A Kurdziel; William D Figg; Jorge Carrasquillo; Susan Huebsch; Millie Whatley; David Sellers; Steven Libutti; James M Pluda; William Dahut; Edward Reed; Stephen L Bacharach
Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2003;5(2):86-93.
2003: McDonald K Horne; William D Figg; Philip M Arlen; James L Gulley; Catherine Parker; Nehal J Lakhani; Howard L Parnes; William L Dahut
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Pharmacotherapy 2003;23(3):315-8.
2003: Nehal J Lakhani; Mohamadi A Sarkar; Jürgen Venitz; William D Figg
2-Methoxyestradiol, a promising anticancer agent.
Pharmacotherapy 2003;23(2):165-72.
2003: Richard A Messmann; Claudio Dansky Ullmann; Tyler Lahusen; Audrey Kalehua; Jason Wasfy; Giovanni Melillo; Ivan Ding; Donna Headlee; William D Figg; Edward A Sausville; Adrian M Senderowicz
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):562-70.
2003: Suoping Zhai; Edward A Sausville; Adrian M Senderowicz; Yuichi Ando; Donna Headlee; Richard A Messmann; Arbuck Susan; Anthony J Murgo; Giovanni Melillo; Eiichi Fuse; William D Figg
Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Anti-cancer drugs 2003;14(2):125-35.
2003: Gregory D Leonard; William L Dahut; James L Gulley; Philip M Arlen; William D Figg
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer.
Reviews in urology 2003;5 Suppl 3():S65-70.
2003: James L Gulley; William D Figg; William L Dahut
Treatment options for androgen-independent prostate cancer.
Clinical advances in hematology & oncology : H&O 2003;1(1):49-57.
2003: Michael Hamilton; William Dahut; Otis W Brawley; Patricia Davis; Toni Wells-Jones; David R Kohler; Paul H Duray; David J Liewehr; Nehal J Lakhani; Seth M Steinberg; William D Figg; Eddie Reed
A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer.
Acta oncologica (Stockholm, Sweden) 2003;42(3):195-201.
2003: Edward M Uchio; W Marston Linehan; William D Figg; McClellan Walther
A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
The Journal of urology 2003;169(1):357-60.
2002: Philip M Arlen; William D Figg; James L Gulley; Michael C Cox; W Marston Linehan; William Dahut
National Cancer Institute intramural approach to advanced prostate cancer.
Clinical prostate cancer 2002;1(3):153-62.
2002: David S Schrump; Dao Nguyen; Tricia E Kunst; Ana Hancox; William D Figg; Seth M Steinberg; Vitality Pishchik; Yvonne Becerra
Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura.
Clinical lung cancer 2002;4(3):186-92.
2002: Yuichi Ando; Douglas K Price; William L Dahut; Michael C Cox; Eddie Reed; William D Figg
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.
Cancer biology & therapy 2002;1(6):669-73.
2002: John L Marshall; Naiyer A Rizvi; John Kauh; William Dahut; Manuela Figuera; Min H Kang; William D Figg; irving william wainer; Christoff Chaissang; Megan Zhaoyang Li; Michael J Hawkins
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.
Journal of experimental therapeutics & oncology 2002;2(6):325-32.
2002: Antoinette R Tan; Donna Headlee; Richard A Messmann; Edward A Sausville; Arbuck Susan; Anthony J Murgo; Giovanni Melillo; Suoping Zhai; William D Figg; Sandra M Swain; Adrian M Senderowicz
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4074-82.
2002: TG Zogakis; Nick G Costouros; Erwin A Kruger; S Forbes; M He; M Qian; Andrew L Feldman; William D Figg; H Richard Alexander; Edison Liu; E C Kohn; Steven Libutti
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.
BioTechniques 2002;33(3):664-6, 668, 670.
2002: Suoping Zhai; Edward A Sausville; William D Figg
A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.
Biomedical chromatography : BMC 2002;16(6):379-82.
2002: Charles L Bennett; Douglas K Price; Simon Kim; Dachao Liu; Borko D Jovanovic; Derek Nathan; Margaret E Johnson; Jeffrey S Montgomery; Kelly Cude; Justin C Brockbank; Oliver Sartor; William D Figg
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3599-604.
2002: Mikhail V Blagosklonny; Zbigniew Darzynkiewicz; William D Figg
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel.
Cancer biology & therapy 2002;1(4):420-5.
2002: Sylvia S W Ng; M Brown; William D Figg
Thalidomide, an antiangiogenic agent with clinical activity in cancer.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2002;56(4):194-9.
2002: MICHELLE RUDEK-RENAUT; Jürgen Venitz; William D Figg
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Pharmacotherapy 2002;22(6):705-20.
2002: Yuichi Ando; Eiichi Fuse; William D Figg
Thalidomide metabolism by the CYP2C subfamily.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1964-73.
2002: Yuichi Ando; William D Figg
Irinotecan in small-cell lung cancer.
The New England journal of medicine 2002;346(18):1414-5; author reply 1414-5.
2002: Maninderjeet Kaur; Eddie Reed; Oliver Sartor; William Dahut; William D Figg
Suramin's development: what did we learn?
Investigational new drugs 2002;20(2):209-19.
2002: William D Figg; Erwin A Kruger; Douglas K Price; Sonia Kim; William Dahut
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.
Investigational new drugs 2002;20(2):183-94.
2002: Suoping Zhai; Adrian M Senderowicz; Edward A Sausville; William D Figg
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
The Annals of pharmacotherapy 2002;36(5):905-11.
2002: David S Schrump; Suoping Zhai; Dao Nguyen; Todd S Weiser; Bradley A Fisher; Richard E Terrill; Bernard M Flynn; Paul H Duray; William D Figg
Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques.
The Journal of thoracic and cardiovascular surgery 2002;123(4):686-94.
2002: Richard Béliveau; Denis Gingras; Erwin A Kruger; Sylvie Lamy; Pierre Sirois; Bryan Simard; Martin G Sirois; Leone Tranqui; Fabienne Baffert; Edith Beaulieu; Violetta Dimitriadou; Marie-Claude Pépin; Frank Courjal; Isabelle Ricard; Patrick Poyet; Pierre Falardeau; William D Figg; Eric Dupont
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1242-50.
2002: Steven D Gore; Li-Jun Weng; William D Figg; Suoping Zhai; Ross C Donehower; George J Dover; Michael R Grever; Constance A Griffin; Louise B. Grochow; Anita E Hawkins; Kathleen Burks; Yelena Zabelena; Carole B Miller
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):963-70.
2002: Victor A Sandor; Susan Bakke; Robert W Robey; Min H Kang; Mikhail V Blagosklonny; Jonathon Bender; Rebecca Brooks; Richard L Piekarz; Eben Tucker; William D Figg; Kenneth K Chan; Barry Goldspiel; Antonio Tito Fojo; Stanley P Balcerzak; Susan E Bates
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):718-28.
2002: Douglas K Price; Yuichi Ando; Erwin A Kruger; Michael Weiss; William D Figg
5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.
Therapeutic drug monitoring 2002;24(1):104-10.
2002: Gordon R Macpherson; Sylvia S W Ng; Nehal J Lakhani; Douglas K Price; Jürgen Venitz; William D Figg
Antiangiogenesis therapeutic strategies in prostate cancer.
Cancer metastasis reviews 2002;21(1):93-106.
2002: Susan F Bates; Clara Chen; Robert W Robey; Min Kang; William D Figg; Tito Fojo
Reversal of multidrug resistance: lessons from clinical oncology.
Novartis Foundation symposium 2002;243():83-96; discussion 96-102, 180-5.
2002: Sattva S Neelapu; William D Figg; William Dahut; Eddie Reed
Leptomeningeal carcinomatosis in metastatic prostate cancer.
Southern medical journal 2002;95(1):107-8.
2002: Kelly J Cude; Jeffrey S Montgomery; Douglas K Price; Shannon C Dixon; Randall L Kincaid; Karl F Kovacs; David J Venzon; David J Liewehr; Margaret E Johnson; Eddie Reed; William D Figg
The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer.
Urologia internationalis 2002;68(1):16-23.
2002: Mary Cianfrocca; Timothy P Cooley; Jeannette Y Lee; MICHELLE RUDEK-RENAUT; David T Scadden; Lee Ratner; James M Pluda; William D Figg; Susan E Krown; Bruce J Dezube
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):153-9.
2001: Erwin A Kruger; Paul H Duray; Douglas K Price; James M Pluda; William D Figg
Approaches to preclinical screening of antiangiogenic agents.
Seminars in oncology 2001;28(6):570-6.
2001: Susan Bates; Min Kang; Beverly Meadows; Susan Bakke; Peter Choyke; Maria Merino; Barry Goldspiel; Isagani M Chico; Tom Smith; Chu Chen; Robert W Robey; Raymond C Bergan; William D Figg; Tito Fojo
A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Cancer 2001;92(6):1577-90.
2001: Jeffrey S Montgomery; Douglas K Price; William D Figg
The androgen receptor gene and its influence on the development and progression of prostate cancer.
The Journal of pathology 2001;195(2):138-46.
2001: Jorge Carrasquillo; Millie Whatley; V Dyer; William D Figg; William Dahut
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(9):1359-63.
2001: E W Woo; Richard A Messmann; Edward A Sausville; William D Figg
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(2):247-57.
2001: William D Figg; Philip M Arlen; James L Gulley; P Fernandez; MH Noone; Kathy Fedenko; Michael Hamilton; C Parker; Erwin A Kruger; James M Pluda; William L Dahut
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Seminars in oncology 2001;28(4 Suppl 15):62-6.
2001: E Chang; H Richard Alexander; Steven Libutti; R Hurst; Suoping Zhai; William D Figg; David L Bartlett
Laparoscopic continuous hyperthermic peritoneal perfusion.
Journal of the American College of Surgeons 2001;193(2):225-9.
2001: Steven D Gore; Li-Jun Weng; Suoping Zhai; William D Figg; Ross C Donehower; George J Dover; Michael R Grever; Constance A Griffin; Louise B. Grochow; Eric K Rowinsky; Y Zabalena; Anita L Hawkins; Kathleen Burks; Carole B Miller
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2330-9.
2001: J Gilbert; Sharyn D Baker; M Kathy Bowling; Louise B. Grochow; William D Figg; Yelena Zabelina; Ross C Donehower; Michael A Carducci
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2292-300.
2001: Fiona M Molloy; Mary Kay Floeter; Nadir A Syed; F Sandbrink; E Culcea; S M Steinberg; William Dahut; James M Pluda; Erwin A Kruger; E Reed; William D Figg
Thalidomide neuropathy in patients treated for metastatic prostate cancer.
Muscle & nerve 2001;24(8):1050-7.
2001: William D Figg; William Dahut; Paul H Duray; Michael Hamilton; AC Tompkins; Seth M Steinberg; Elizabeth Jones; Ahalya Premkumar; W Marston Linehan; Mary Kay Floeter; Clara C Chen; S Dixon; David R Kohler; E A Krüger; E Gubish; James M Pluda; Eddie Reed
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1888-93.
2001: E A Krüger; William D Figg
Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1867-72.
2001: M H Kang; William D Figg; Yuichi Ando; Mikhail V Blagosklonny; David J Liewehr; Tito Fojo; Susan E Bates
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1610-7.
2001: Elise C Kohn; Eddie Reed; Gisele Sarosy; Lori M Minasian; Kenneth S. Bauer; F Bostick-Bruton; Vyta Kulpa; Eiichi Fuse; AC Tompkins; MH Noone; Barry Goldspiel; James M Pluda; William D Figg; Lance A Liotta
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1600-9.
2001: MICHELLE RUDEK-RENAUT; McDonald Horne; William D Figg; William Dahut; V Dyer; James M Pluda; Eddie Reed
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.
American journal of hematology 2001;67(1):51-3.
2001: Edward A Sausville; Arbuck Susan; Richard A Messmann; Donna Headlee; Kenneth S. Bauer; Richard M Lush; Anthony J Murgo; William D Figg; Tyler Lahusen; S Jaken; X Jing ; M Roberge; Eiichi Fuse; Takashi Kuwabara; Adrian M Senderowicz
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2319-33.
2001: J V Ghate; Maria L Turner; MICHELLE RUDEK-RENAUT; William D Figg; William Dahut; V Dyer; James M Pluda; Eddie Reed
Drug-induced lupus associated with COL-3: report of 3 cases.
Archives of dermatology 2001;137(4):471-4.
2001: Mikhail V Blagosklonny; Shannon C Dixon; Robert W Robey; William D Figg
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.
International journal of oncology 2001;18(4):697-704.
2001: AH Burstein; Eddie Reed; AC Tompkins; D Venzon; William D Figg
Phenylacetate pharmacokinetics based on iterative two-stage population analysis.
Pharmacotherapy 2001;21(3):281-6.
2001: Shannon C Dixon; Kevin B Knopf; William D Figg
The control of prostate-specific antigen expression and gene regulation by pharmacological agents.
Pharmacological reviews 2001;53(1):73-91.
2001: David L Bartlett; Steven Libutti; William D Figg; Douglas L Fraker; H Richard Alexander
Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
Surgery 2001;129(2):176-87.
2001: Isagani M Chico; M H Kang; Raymond C Bergan; Jame Abraham; Susan Bakke; Beverly Meadows; Ann Rutt; Robert W Robey; Peter Choyke; Maria Merino; Barry Goldspiel; Tom Smith; S Steinberg; William D Figg; Tito Fojo; Susan Bates
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):832-42.
2001: John B Sunwoo; Laurie L Herscher; Glenn S Kroog; Giovana R Thomas; Frank G Ondrey; Dianne C Duffey; BI Solomon; C Boss; Paul S Albert; L McCullugh; Susan F Rudy; Christine Muir; S Zhai; William D Figg; John A Cook; James B Mitchell; Carter Van Waes
Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):800-11.
2001: MICHELLE RUDEK-RENAUT; William D Figg; V Dyer; William Dahut; Maria L Turner; Seth M Steinberg; David J Liewehr; David R Kohler; James M Pluda; Eddie Reed
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):584-92.
2000: McClellan Walther; Nadja N Rehak; David Venzon; Charles E Myers; W Marston Linehan; William D Figg
Suramin administration is associated with a decrease in serum calcium levels.
World journal of urology 2000;18(6):388-91.
2000: Kenneth S. Bauer; Richard M Lush; MICHELLE RUDEK-RENAUT; C Shih; Edward A Sausville; William D Figg
A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.
Biomedical chromatography : BMC 2000;14(5):338-43.
2000: Richard F Little; Kathleen M Wyvill; James M Pluda; Lauri Welles; Vickie Marshall; William D Figg; Fonda M Newcomb; Giovanna Tosato; Ellen G Feigal; Seth M Steinberg; Denise Whitby; James J Goedert; Robert Yarchoan
Activity of thalidomide in AIDS-related Kaposi's sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(13):2593-602.
2000: Adam C Berger; H Richard Alexander; G Tang; P S Wu; Stephen M Hewitt; Ewa Turner; Erwin A Kruger; William D Figg; A Grove; E Kohn; D Stern; Steven Libutti
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Microvascular research 2000;60(1):70-80.
2000: MICHELLE RUDEK-RENAUT; C L March; Kenneth S. Bauer; James M Pluda; William D Figg
High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma.
Journal of pharmaceutical and biomedical analysis 2000;22(6):1003-14.
2000: E A Kruger; William D Figg
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
Expert opinion on investigational drugs 2000;9(6):1383-96.
2000: Adam C Berger; Andrew L Feldman; Michael F X Gnant; Erwin A Kruger; B K Sim; Stephen Hewitt; William D Figg; H Richard Alexander; Steven Libutti
The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.
The Journal of surgical research 2000;91(1):26-31.
2000: Richard A Messmann; Ellen S Vitetta; Donna Headlee; Adrian M Senderowicz; William D Figg; John Schindler; D F Michiel; Stephen Creekmore; Seth M Steinberg; David R Kohler; Elaine S Jaffe; Maryalice Stetler-Stevenson; H Chen; Victor Ghetie; Edward A Sausville
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1302-13.
2000: Mikhail V Blagosklonny; Shannon C Dixon; William D Figg
Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
The Journal of urology 2000;163(3):1022-6.
2000: Erwin A Kruger; Paul H Duray; M G Tsokos; David J Venzon; Steven Libutti; Shannon C Dixon; MICHELLE RUDEK-RENAUT; James M Pluda; Carmen J Allegra; William D Figg
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.
Biochemical and biophysical research communications 2000;268(1):183-91.
2000: Wyndham H Wilson; Lynn Sorbara; William D Figg; E K Mont; Edward A Sausville; Katherine E Warren; FRANK BALIS; Kenneth S. Bauer; Mark Raffeld; Adrian M Senderowicz; Anne Monks
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):415-21.
2000: Kenneth S. Bauer; Kelly J Cude; Shannon C Dixon; Erwin A Kruger; William D Figg
Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.
The Journal of pharmacology and experimental therapeutics 2000;292(1):31-7.
1999: Glenn J Bubley; Michael A Carducci; William Dahut; Nancy A Dawson; Danai D Daliani; Mario A Eisenberger; William D Figg; B Freidlin; Susan Halabi; Gary R Hudes; Maha Hussain; Richard S. Kaplan; C Myers; William K Oh; Daniel P Petrylak; Eddie Reed; B Roth; Oliver Sartor; Howard I Scher; J Simons; Victoria Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3461-7.
1999: M H Kang; William D Figg; William Dahut
Taxanes in hormone-refractory prostate cancer.
Cancer practice 1999;7(5):270-2.
1999: Raymond C Bergan; Eddie Reed; Charles E Myers; Donna Headlee; Otis W Brawley; H K Cho; William D Figg; AC Tompkins; W Marston Linehan; David R Kohler; Seth M Steinberg; Mikhail V Blagosklonny
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2366-73.
1999: Kenneth S. Bauer; William D Figg; J Michael Hamilton; Elizabeth C Jones; Ahalya Premkumar; Seth M Steinberg; V Dyer; W Marston Linehan; James M Pluda; Eddie Reed
A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2324-9.
1999: Kelly J Cude; Shannon C Dixon; Y Guo; J Lisella; William D Figg
The androgen receptor: genetic considerations in the development and treatment of prostate cancer.
Journal of molecular medicine (Berlin, Germany) 1999;77(5):419-26.
1999: Bernard J Park; CK Brown; Y Hu; H Richard Alexander; J Horti; Sangeeta Raje; William D Figg; David L Bartlett
Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma.
Human gene therapy 1999;10(6):889-98.
1999: H K Cho; Richard M Lush; David L Bartlett; H Richard Alexander; Peter C Wu; Steven Libutti; KB Lee; David J Venzon; Kenneth S. Bauer; Eddie Reed; William D Figg
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
Journal of clinical pharmacology 1999;39(4):394-401.
1999: J Horti; Shannon C Dixon; C J Logothetis; Y Guo; Eddie Reed; William D Figg
Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor.
British journal of cancer 1999;79(9-10):1588-93.
1999: Adrian M Senderowicz; R Reid; Donna Headlee; T Abornathy; J Horti; Richard M Lush; Eddie Reed; William D Figg; Edward A Sausville
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
Urologia internationalis 1999;63(2):120-5.
1999: IN Arah; Shannon C Dixon; J Horti; William D Figg
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Neoplasma 1999;46(2):117-23.
1999: Shannon C Dixon; Erwin A Kruger; Kenneth S. Bauer; William D Figg
Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.
Cancer chemotherapy and pharmacology 1999;43 Suppl():S78-84.
1999: William D Figg; Sangeeta Raje; Kenneth S. Bauer; AC Tompkins; David Venzon; Raymond C Bergan; A Chen; Michael Hamilton; James M Pluda; Eddie Reed
Pharmacokinetics of thalidomide in an elderly prostate cancer population.
Journal of pharmaceutical sciences 1999;88(1):121-5.
1998: Kenneth S. Bauer; Elise C Kohn; Richard M Lush; Seth M Steinberg; P Davis; David R Kohler; Eddie Reed; William D Figg
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
Journal of pharmacokinetics and biopharmaceutics 1998;26(6):673-87.
1998: Stephen C Piscitelli; Stefanie N Vogel; William D Figg; Sangeeta Raje; A Forrest; Julia A Metcalf; Michael Baseler; Judith Falloon
Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Pharmacotherapy 1998;18(6):1212-6.
1998: H Richard Alexander; CK Brown; David L Bartlett; Steven Libutti; William D Figg; Sangeeta Raje; Ewa Turner
Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2357-62.
1998: David L Bartlett; J F Buell; Steven Libutti; Eddie Reed; KB Lee; William D Figg; David J Venzon; H Richard Alexander
A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Cancer 1998;83(6):1251-61.
1998: Adrian M Senderowicz; Donna Headlee; Sherman F Stinson; Richard M Lush; N Kalil; L Villalba; K Hill; Seth M Steinberg; William D Figg; AC Tompkins; Arbuck Susan; Edward A Sausville
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2986-99.
1998: Eiichi Fuse; H Tanii; N Kurata; Hiroyuki Kobayashi; Y Shimada; T Tamura; Y Sasaki; Y Tanigawara; R D Lush; Donna Headlee; William D Figg; Arbuck Susan; Adrian M Senderowicz; Edward A Sausville; Shiro Akinaga; Takashi Kuwabara; S Kobayashi
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
Cancer research 1998;58(15):3248-53.
1998: J Horti; William D Figg; B Weinberger; David R Kohler; Oliver Sartor
A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
Oncology reports 1998;5(4):893-6.
1998: Kenneth S. Bauer; Shannon C Dixon; William D Figg
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.
Biochemical pharmacology 1998;55(11):1827-34.
1998: Lauri Welles; MW Saville; JA Lietzau; James M Pluda; Kathleen M Wyvill; I Feuerstein; William D Figg; Richard M Lush; J Odom; Wyndham H Wilson; M T Fajardo; Rachel Humphrey; Ellen G Feigal; David Tuck; Seth M Steinberg; S Broder; Robert Yarchoan
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1112-21.
1998: J A Feuer; Richard M Lush; David Venzon; Paul H Duray; AC Tompkins; Oliver Sartor; William D Figg
Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 1998;46(2):66-72.
1998: Erwin A Kruger; Mikhail V Blagosklonny; Shannon C Dixon; William D Figg
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.
Invasion & metastasis 1998;18(4):209-18.
1998: Edward A Sausville; R D Lush; Donna Headlee; A C Smith; William D Figg; Arbuck Susan; Adrian M Senderowicz; Eiichi Fuse; H Tanii; Takashi Kuwabara; S Kobayashi
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S54-9.
1998: A Thibault; William D Figg; Raymond C Bergan; Richard M Lush; Charles E Myers; AC Tompkins; Eddie Reed; D Samid
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.
Tumori 1998;84(1):87-9.
1998: Nancy A Dawson; William D Figg; Otis W Brawley; Raymond C Bergan; MR Cooper; Adrian M Senderowicz; Donna Headlee; Seth M Steinberg; M Sutherland; Nicholas Patronas; Edward A Sausville; W Marston Linehan; Eddie Reed; Oliver Sartor
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):37-44.
1998: Shannon C Dixon; J Horti; Y Guo; Eddie Reed; William D Figg
Methods for extracting and amplifying genomic DNA isolated from frozen serum.
Nature biotechnology 1998;16(1):91-4.
1997: Stephen C Piscitelli; William D Figg; Barbara Hahn; G Kelly; S Thomas; Robert E Walker
Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 1997;41(12):2797-9.
1997: THOMAS WALSH; Patricia Whitcomb; Stephen C Piscitelli; William D Figg; S Hill; STEPHEN CHANOCK; Paul F Jarosinski; R Gupta; PA Pizzo
Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
Antimicrobial agents and chemotherapy 1997;41(9):1944-8.
1997: Raymond C Bergan; R G Walls; William D Figg; Nancy A Dawson; Donna Headlee; AC Tompkins; Seth M Steinberg; Eddie Reed
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.
Journal of the National Medical Association 1997;89(9):622-8.
1997: William D Figg; J A Feuer; Kenneth S. Bauer
Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy.
Cancer practice 1997;5(4):258-63.
1997: Adrian M Senderowicz; Ellen S Vitetta; Donna Headlee; Victor Ghetie; Jonathan Uhr; William D Figg; Richard M Lush; Maryalice Stetler-Stevenson; G Kershaw; Douglas W Kingma; Elaine S Jaffe; Edward A Sausville
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Annals of internal medicine 1997;126(11):882-5.
1997: William D Figg; Glenn S Kroog; Paul H Duray; McClellan Walther; N Patronas; Oliver Sartor; Eddie Reed
Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Cancer 1997;79(10):1964-8.
1997: Stephen C Piscitelli; A Forrest; Richard M Lush; N Ryan; L R Whitfield; William D Figg
Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Pharmacotherapy 1997;17(3):431-7.
1997: Elise C Kohn; William D Figg; Gisele Sarosy; Kenneth S. Bauer; P A Davis; M J Soltis; A Thompkins; Lance A Liotta; Eddie Reed
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1985-93.
1997: G Y Ma; David L Bartlett; Eddie Reed; William D Figg; Richard M Lush; KB Lee; Steven Libutti; H Richard Alexander
Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
The cancer journal from Scientific American 1997;3(3):174-9.
1997: William D Figg; Michaele C Christian; Richard M Lush; Charles J. Link; P Davis; Elise C Kohn; Gisele Sarosy; M L Rothenberg; R B Weiss; N Ryan; J Jacobs; Eddie Reed
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Biopharmaceutics & drug disposition 1997;18(4):347-59.
1997: Nancy A Dawson; William D Figg; MR Cooper; Oliver Sartor; Raymond C Bergan; Adrian M Senderowicz; Seth M Steinberg; AC Tompkins; B Weinberger; Edward A Sausville; Eddie Reed; Charles E Myers
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1470-7.
1997: Shannon C Dixon; A Zalles; C Giordano; Richard M Lush; David Venzon; Eddie Reed; William D Figg
In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.
Cancer letters 1997;113(1-2):111-6.
1997: Richard M Lush; Beverly Meadows; Antonio Tito Fojo; G Kalafsky; H T Smith; Susan Bates; William D Figg
Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
Journal of clinical pharmacology 1997;37(2):123-8.
1997: William D Figg; James M Pluda; Richard M Lush; MW Saville; Kathleen M Wyvill; Eddie Reed; Robert Yarchoan
The pharmacokinetics of TNP-470, a new angiogenesis inhibitor.
Pharmacotherapy 1997;17(1):91-7.
1997: Shannon C Dixon; B J Soriano; Richard M Lush; M M Borner; William D Figg
Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target.
The Annals of pharmacotherapy 1997;31(1):76-82.
1996: S Boudoulas; Richard M Lush; N A McCall; D Samid; E Reed; William D Figg
Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents.
Therapeutic drug monitoring 1996;18(6):714-20.
1996: Richard M Lush; William D Figg; James M Pluda; R Bitton; Donna Headlee; David R Kohler; Eddie Reed; Oliver Sartor; MR Cooper
A phase I study of pentosan polysulfate sodium in patients with advanced malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(9):939-44.
1996: R Walls; A Thibault; L Liu; C Wood; J M Kozlowski; William D Figg; M L Sampson; R J Elin; D Samid
The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells.
The Prostate 1996;29(3):177-82.
1996: lee stone; Edward A Sausville; Joseph W Fay; Donna Headlee; Robert H Collins; William D Figg; Maryalice Stetler-Stevenson; V Jain; E S Jaffe; D Solomon; Richard M Lush; Adrian M Senderowicz; Victor Ghetie; J Schindler; J W Uhr; Ellen S Vitetta
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Blood 1996;88(4):1188-97.
1996: Nancy A Dawson; Richard M Lush; Seth M Steinberg; AC Tompkins; Donna Headlee; William D Figg
Suramin-induced neutropenia.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1534-9.
1996: M N Middleman; Richard M Lush; William D Figg
The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Pharmacotherapy 1996;16(3):376-81.
1996: A Thibault; D Samid; AC Tompkins; William D Figg; MR Cooper; R J Hohl; Jane Trepel; B Liang; N Patronas; D J Venzon; Eddie Reed; Charles E Myers
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):483-91.
1996: M N Middleman; Richard M Lush; Oliver Sartor; Eddie Reed; William D Figg
Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.
Cancer treatment reviews 1996;22(2):105-18.
1996: J F Tisdale; William D Figg; E Reed; N A McCall; B R Alkins; McDonald K Horne
Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
American journal of hematology 1996;51(2):152-7.
1996: Elise C Kohn; Eddie Reed; Gisele Sarosy; M Christian; Charles J. Link; K Cole; William D Figg; P A Davis; J Jacob; Barry Goldspiel; Lance A Liotta
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Cancer research 1996;56(3):569-73.
1996: C J Bowden; William D Figg; Nancy A Dawson; Oliver Sartor; R J Bitton; M S Weinberger; Donna Headlee; Eddie Reed; Charles E Myers; MR Cooper
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Cancer chemotherapy and pharmacology 1996;39(1-2):1-8.
1996: William D Figg; K Ammerman; N Patronas; Seth M Steinberg; R G Walls; Nancy A Dawson; Eddie Reed; Oliver Sartor
Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer.
Cancer investigation 1996;14(6):513-7.
1996: William D Figg; Nancy A Dawson; M N Middleman; Otis W Brawley; Richard M Lush; Adrian M Senderowicz; S H Steinberg; AC Tompkins; Eddie Reed; Oliver Sartor
Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
Acta oncologica (Stockholm, Sweden) 1996;35(6):763-5.
1996: McClellan Walther; William D Figg; W Marston Linehan
Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
World journal of urology 1996;14 Suppl 1():S8-11.
1995: R J Bitton; William D Figg; D J Venzon; Marinos C Dalakas; C Bowden; Donna Headlee; Eddie Reed; Charles E Myers; MR Cooper
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2223-9.
1995: William D Figg; Kristina A Cole; Eddie Reed; Seth M Steinberg; S C Piscitelli; P A Davis; M J Soltis; J Jacob; S Boudoulas; Barry Goldspiel
Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(8):797-803.
1995: Nancy A Dawson; MR Cooper; William D Figg; Donna Headlee; A Thibault; Raymond C Bergan; Seth M Steinberg; Edward A Sausville; Charles E Myers; Oliver Sartor
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Cancer 1995;76(3):453-62.
1995: Edward A Sausville; Donna Headlee; Maryalice Stetler-Stevenson; Elaine S Jaffe; D Solomon; William D Figg; J Herdt; William Kopp; H Rager; Seth M Steinberg
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
Blood 1995;85(12):3457-65.
1995: A Thibault; D Samid; MR Cooper; William D Figg; AC Tompkins; N Patronas; Donna Headlee; David R Kohler; D J Venzon; Charles E Myers
Phase I study of phenylacetate administered twice daily to patients with cancer.
Cancer 1995;75(12):2932-8.
1995: William D Figg; A Thibault; MR Cooper; R Reid; Donna Headlee; Nancy A Dawson; David R Kohler; Eddie Reed; Oliver Sartor
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.
Cancer 1995;75(8):2159-64.
1995: S C Piscitelli; A Thibault; William D Figg; AC Tompkins; Donna Headlee; R Lieberman; D Samid; Charles E Myers
Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.
Journal of clinical pharmacology 1995;35(4):368-73.
1995: William D Figg; Oliver Sartor; MR Cooper; A Thibault; Raymond C Bergan; Nancy A Dawson; Eddie Reed; Charles E Myers
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
The American journal of medicine 1995;98(4):412-4.
1995: R J Bitton; William D Figg; Eddie Reed
A preliminary risk-benefit assessment of paclitaxel.
Drug safety : an international journal of medical toxicology and drug experience 1995;12(3):196-208.
1994: Francine M Foss; T A Borkowski; M Gilliom; Maryalice Stetler-Stevenson; Elaine S Jaffe; William D Figg; AC Tompkins; A Bastian; P Nylen; T Woodworth
Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
Blood 1994;84(6):1765-74.
1994: William D Figg; MR Cooper; A Thibault; Donna Headlee; J Humphrey; Raymond C Bergan; Eddie Reed; Oliver Sartor
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Cancer 1994;74(5):1612-4.
1994: William D Figg; R G Walls; MR Cooper; A Thibault; Oliver Sartor; N A McCall; Charles E Myers; D Samid
In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate.
Anti-cancer drugs 1994;5(3):336-42.
1994: William D Figg; A Thibault; A O Sartor; D Mays; Donna Headlee; K A Calis; MR Cooper
Hypothyroidism associated with aminoglutethimide in patients with prostate cancer.
Archives of internal medicine 1994;154(9):1023-5.
1994: A Thibault; MR Cooper; William D Figg; D J Venzon; A O Sartor; AC Tompkins; M S Weinberger; Donna Headlee; N A McCall; D Samid
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
Cancer research 1994;54(7):1690-4.
1994: William D Figg; H J Yeh; A Thibault; James M Pluda; F Itoh; Robert Yarchoan; MR Cooper
Assay of the antiangiogenic compound TNP-470, and one of its metabolites, AGM-1883, by reversed-phase high-performance liquid chromatography in plasma.
Journal of chromatography 1994;652(2):187-94.
1994: Oliver Sartor; M Cooper; M Weinberger; Donna Headlee; A Thibault; AC Tompkins; S Steinberg; William D Figg; W Marston Linehan; Charles E Myers
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
Journal of the National Cancer Institute 1994;86(3):222-7.
1993: A Thibault; William D Figg; MR Cooper; S A Prindiville; A O Sartor; Donna Headlee; Charles E Myers
Anaphylactoid reaction with suramin.
Pharmacotherapy 1993;13(6):656-7.